Scale -


  • PBT is 43.17 Rs Cr; Continuous Growth over 3 years; in Top Quartile
  • Quarterly Revenue is 104 Rs Cr; Continuous Growth over 3 Quarters
  • Quarterly Profit is 32.21 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile
  • PAT is 93.18 Rs Cr; in Top Quartile
  • Ebitda is 133 Rs Cr; 5 Year CAGR is 22 %

Profitability -


  • Quarterly Profit margin is 31 %; Continuous Growth over 3 Quarters; in Top Quartile
  • PBDIT Margin is 37.49 %; in Top Quartile; 5 Year CAGR is 26 %
  • PAT Margin is 26.29 %; in Top Quartile
  • Quarterly Ebitda Margin is 34 %; in Top Quartile

Return -


  • ROCE is 15.71 %; 5 Year CAGR is 23 %
  • Asset Turnover is 37 %; in Bottom Quartile

Efficiency -


  • Current Ratio is 5.3; Continuous Growth over 3 years; in Top Quartile
  • Quick Ratio is 4.93; in Top Quartile
  • Operating cash flow is 46.73 Rs Cr; Annual Decline is -37 %; Continuous Decline over 3 years

Solvancy -


  • Debt/Equity is 0; in Bottom Quartile
  • Total Debt is 0 Rs Cr; in Bottom Quartile
  • Contingent Liabilities is 388 Rs Cr; in Top Quartile

Quality -


  • Change in Inventories/Total Expenses is -5 %; Annual Decline is -431 %; Continuous Decline over 3 years; in Bottom Quartile
  • Other Expenses/Total Expenses is 16 %; Continuous Decline over 3 years
  • Operating cashflow/ebitda is 35 %; Annual Decline is -37 %; Continuous Decline over 3 years
  • Operating cashflow/PAT is 50 %; Annual Decline is -32 %; Continuous Decline over 3 years
  • Current Tax/PAT is 38 %; Annual Growth is 26 %; in Top Quartile
  • Exceptional Items/PBT is 0 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Novartis India share price jumps 10% | What lies ahead for the stock?
Evonile Pharma (NSEI:NOVARTIND)
Novartis' listed entity renamed to Evonile Pharma Limited
Novartis India Limited Rebrands as Evonile Pharma Limited Following MCA Approval